Marker Therapeutics awarded $2.6 million FDA grant to advance MT-601 in pancreatic cancer
MRKR•Marker Therapeutics was awarded a $2.6 million FDA Orphan Products Development grant to support a Phase 1 study of MT-601 in pancreatic cancer.
1. Grant supports study
Marker Therapeutics was awarded a $2.6 million FDA Orphan Products Development grant to support a Phase 1 study of MT-601 in pancreatic cancer.
